March 28, 2019
Company to host business update call and webcast today at 5:00 p.m. EDT
March 18, 2019
Marker Therapeutics announces business update conference call and webcast on Thursday, March 28th.
February 25, 2019
Marker Therapeutics announces updated data from four clinical trials using the Company’s multi-antigen targeted T cell (MultiTAA) therapies.
February 21, 2019
Marker Therapeutics would like to congratulate Scientific Advisory Board Member, Helen E. Heslop, MD, DSc (Hon), on receiving the ASBMT Lifetime Achievement Award.
February 20, 2019
President and CEO, Peter L. Hoang, and Chief Development Officer, Dr. Juan Vera, will be presenting at the CAR-TCR Summit Europe.
February 15, 2019
Marker Therapeutics has formally relocated their corporate headquarters from Jacksonville, Florida to Houston, Texas. In addition, the Company has announced that it is now a resident company at Johnson & Johnson Innovation – JLABS (JLABS at TMC).
February 7, 2019
Marker Therapeutics appoints Mythili Koneru, M.D., Ph.D. as Senior Vice President, Clinical Development. In this role, she will be responsible for clinical development strategy, clinical study design, and medical oversight of the Company’s therapeutic product candidates. Dr. Koneru joins Marker Therapeutics from Eli Lilly and Company, where she served most recently as Associate Vice President of Immuno-Oncology.
February 6, 2019
Chief Financial Officer, Anthony H. Kim, to present a corporate overview at the upcoming BIO CEO & Investor Conference on Monday, February 11, 2019.
January 17, 2019
Peter L. Hoang to present a corporate overview at the upcoming Phacilitate Leaders World & World Stem Cell Summit 2019 on January 23, 2019.
January 15, 2019
Data from four abstracts—including three oral presentations—were accepted for presentation at the Transplantation & Cellular Therapy (TCT) Meetings of the American Society for Blood and Marrow Transplantation and the Center for International Blood and Marrow Transplant Research 2019.